The series F financing will allow the company to expand clinical research supporting its unique duodenal mucosal resurfacing approach to treating metabolic disease at its source.
Fractyl Health, formerly called Fractyl Laboratories, closed a $100m Series F financing to support the ongoing development of duodenal mucosal resurfacing (DMR) technology that addresses the root causes of type 2 diabetes, the Massachusetts company announced on 16 June.
“The [ongoing] emergence from the pandemic has created an opportunity for us to begin to accelerate our plans for advancing our clinical programs,” Fractyl
Apple and Synchron are teaming up to develop technologies that will one day allow people who can’t use their hands or voice to control iPhones, iPads and other Apple devices by using only their thoughts.
The REFLECT studies showed a 78% reduction in cardiovascular disease-related hospitalization for people living with type 1 diabetes with prior low blood sugar episodes.
Despite Danaher’s confident outlook, the company acknowledged near-term profitability fluctuations, particularly in the second quarter. Matt McGrew, Danaher’s CFO, clarified during the company’s first-quarter earnings call on 22 April, that expected operating margin softness in the second quarter – forecast at 25.5% – was not related to tariffs, but to seasonal dynamics in its respiratory diagnostics business.
